Category

Prostatic Cancer

Proapoptotic effect of endocannabinoids in prostate cancer cells.

By | Cancer, Prostatic Cancer

Authors: O. Orellana-Serradell, C. E. Poblete, C. Sanchez, E. A. Castellón, I. Gallegos, et al
Oncology Reports, April 2015

In the early stages, prostate cancer is androgen‑ dependent; therefore, medical castration has shown significant results during the initial stages of this pathology. Despite this early effect, advanced prostate cancer is resilient to such treatment. Recent evidence shows that…

Read More

The role of cannabinoids in prostate cancer: Basic science perspective and potential clinical applications.

By | Cancer, Prostatic Cancer

Authors: Juan A. Ramos, Fernando J. Bianco
Indian Journal of Urology, January 2012

Prostate cancer is a global public health problem, and it is the most common cancer in American men and the second cause for cancer-related death. Experimental evidence shows that prostate tissue possesses cannabinoid receptors and their stimulation results in anti-androgenic…

Read More

Inhibition of human tumour prostate PC-3 cell growth by cannabinoids R(+)-Methanandamide and JWH-015: involvement of CB2.

By | Cancer, Prostatic Cancer, Research Articles

Authors: N. Olea-Herrero, D. Vara, S. Malagarie-Cazenave, I. Díaz-Laviada
British Journal of Cancer, 15 September 2009

BACKGROUND: We have previously shown that cannabinoids induce growth inhibition and apoptosis in prostate cancer PC-3 cells, which express high levels of cannabinoid receptor types 1 and 2 (CB(1) and CB(2)). In this study, we investigated the role of CB(2) receptor in the anti…

Read More

Cannabinoids for cancer treatment: progress and promise.

By | Brain Cancer, Breast Cancer, Cancer, Lymphoma, Pancreatic Cancer, Prostatic Cancer, Skin Cancer

Authors: Sami Sarfaraz, Vaqar M. Adhami, Deeba N. Syed, Farrukh Afaq, Hasan Mukhtar
Cancer Research, 15 January 2008

Cannabinoids are a class of pharmacologic compounds that offer potential applications as antitumor drugs, based on the ability of some members of this class to limit inflammation, cell proliferation, and cell survival. In particular, emerging evidence suggests that agonists of…

Read More

Suppression of nerve growth factor Trk receptors and prolactin receptors by endocannabinoids leads to inhibition of human breast and prostate cancer cell proliferation.

By | Breast Cancer, Cancer, Prostatic Cancer

Authors: Dominique Melck, Luciano De Petrocellis, Pierangelo Orlando, Tiziana Bisogno, et al
Endocrinology, January 2000

Anandamide and 2-arachidonoylglycerol (2-AG), two endogenous ligands of the CB1 and CB2 cannabinoid receptor subtypes, inhibit the proliferation of PRL-responsive human breast cancer cells (HBCCs) through down-regulation of the long form of the PRL receptor (PRLr). Here we rep…

Read More